Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer

NCT01003938 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped due to administrative issue and financial sponsor decision to suspend ovarian cancer studies

Conditions

Ovarian Cancer

Interventions

DRUG: Topotecan
DRUG: Erlotinib

Sponsor

NYU Langone Health

Collaborators

[object Object]